House Passes Designer Anabolic Steroid Control Act
The bill would enhance DEA's ability to enforce against supplement spikers by expanding the list of controlled substances.
The Designer Anabolic Steroid Control Act of 2014 (DASCA), which would enhance the U.S. Drug Enforcement Administration’s (DEA) authority to identify and respond to new designer anabolic steroids falsely marketed as dietary supplements, has made it through the U.S. House of Representatives and now moves to a Senate vote.
Dietary supplement association the Council for Responsible Nutrition (CRN; Washington, DC) commended the House for passing the bill and urged the Senate to follow suit.
“If DASCA is passed by Congress and signed into law by the president, DEA’s enhanced authority would help protect consumers from illegal products that could present safety concerns and will give them greater confidence that the products brought to market and sold as dietary supplements are legal,” said Mike Greene, CRN’s vice president, government relations, in a press statement.
CRN says it has been engaged in bipartisan discussions with legislators in both the House of Representatives and the Senate to underline the importance of DASCA to the supplements industry as well as to consumers.
The Designer Anabolic Steroid Act of 2014 (HR. 4771), a companion bill to S. 2012, would enhance DEA's ability to enforce against supplement spikers by expanding the list of controlled substances. Reps. Joe Pitts (R-PA) and Frank Pallone (D-NJ) introduced the bill in the Senate in early 2014.
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine jennifer.grebow@ubm.com
Photo © iStockphoto.com/Mike Rodriguez
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
